128 related articles for article (PubMed ID: 21608069)
1. Hepatic enhancement during the hepatobiliary phase after gadoxetate disodium administration in patients with chronic liver disease: the role of laboratory factors.
Chernyak V; Kim J; Rozenblit AM; Mazzoriol F; Ricci Z
J Magn Reson Imaging; 2011 Aug; 34(2):301-9. PubMed ID: 21608069
[TBL] [Abstract][Full Text] [Related]
2. Biologic factors affecting HCC conspicuity in hepatobiliary phase imaging with liver-specific contrast agents.
Kim JY; Lee SS; Byun JH; Kim SY; Park SH; Shin YM; Lee MG
AJR Am J Roentgenol; 2013 Aug; 201(2):322-31. PubMed ID: 23883212
[TBL] [Abstract][Full Text] [Related]
3. Improved parenchymal liver enhancement with extended delay on Gd-EOB-DTPA-enhanced MRI in patients with parenchymal liver disease: associated clinical and imaging factors.
Esterson YB; Flusberg M; Oh S; Mazzariol F; Rozenblit AM; Chernyak V
Clin Radiol; 2015 Jul; 70(7):723-9. PubMed ID: 25921617
[TBL] [Abstract][Full Text] [Related]
4. Gadoxetate disodium-enhanced hepatic MRI: dose-dependent contrast dynamics of hepatic parenchyma and portal vein.
Feuerlein S; Boll DT; Gupta RT; Ringe KI; Marin D; Merkle EM
AJR Am J Roentgenol; 2011 Jan; 196(1):W18-24. PubMed ID: 21178026
[TBL] [Abstract][Full Text] [Related]
5. The value of gadoxetate disodium-enhanced MR imaging for predicting posthepatectomy liver failure after major hepatic resection: a preliminary study.
Cho SH; Kang UR; Kim JD; Han YS; Choi DL
Eur J Radiol; 2011 Nov; 80(2):e195-200. PubMed ID: 21908121
[TBL] [Abstract][Full Text] [Related]
6. Hepatic steatosis: effect on hepatocyte enhancement with gadoxetate disodium-enhanced liver MR imaging.
Onishi H; Theisen D; Dietrich O; Reiser MF; Zech CJ
J Magn Reson Imaging; 2014 Jan; 39(1):42-50. PubMed ID: 24339365
[TBL] [Abstract][Full Text] [Related]
7. Focal nodular hyperplasia: central scar enhancement pattern using Gadoxetate Disodium.
Karam AR; Shankar S; Surapaneni P; Kim YH; Hussain S
J Magn Reson Imaging; 2010 Aug; 32(2):341-4. PubMed ID: 20677260
[TBL] [Abstract][Full Text] [Related]
8. Hepatic hemangiomas: evaluation of enhancement patterns at dynamic MRI with gadoxetate disodium.
Tamada T; Ito K; Yamamoto A; Sone T; Kanki A; Tanaka F; Higashi H
AJR Am J Roentgenol; 2011 Apr; 196(4):824-30. PubMed ID: 21427331
[TBL] [Abstract][Full Text] [Related]
9. Enhancement patterns and pseudo-washout of hepatic haemangiomas on gadoxetate disodium-enhanced liver MRI.
Kim B; Byun JH; Kim HJ; Won HJ; Kim SY; Shin YM; Kim PN
Eur Radiol; 2016 Jan; 26(1):191-8. PubMed ID: 25933742
[TBL] [Abstract][Full Text] [Related]
10. Liver MRI and histological correlates in chronic liver disease on multiphase gadolinium-enhanced 3D gradient echo imaging.
Martin DR; Lauenstein T; Kalb B; Lurie C; Kitajima H; Sharma P; Salman K; Moreira R; Farris AB; Spivey J; Martinez E; Hanish S; Adsay V
J Magn Reson Imaging; 2012 Aug; 36(2):422-9. PubMed ID: 22566123
[TBL] [Abstract][Full Text] [Related]
11. Relationship between liver function and liver signal intensity in hepatobiliary phase of gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging.
Tajima T; Takao H; Akai H; Kiryu S; Imamura H; Watanabe Y; Shibahara J; Kokudo N; Akahane M; Ohtomo K
J Comput Assist Tomogr; 2010; 34(3):362-6. PubMed ID: 20498536
[TBL] [Abstract][Full Text] [Related]
12. Inter- and intra-reader agreement for gadoxetic acid-enhanced MRI parameter readings in patients with chronic liver diseases.
Beer L; Mandorfer M; Bastati N; Poetter-Lang S; Tamandl D; Stoyanova DP; Elmer MC; Semmler G; Simbrunner B; Hodge JC; Sirlin CB; Reiberger T; Ba-Ssalamah A
Eur Radiol; 2019 Dec; 29(12):6600-6610. PubMed ID: 31001679
[TBL] [Abstract][Full Text] [Related]
13. Comparison of magnetic resonance elastography and gadoxetate disodium-enhanced magnetic resonance imaging for the evaluation of hepatic fibrosis.
Choi YR; Lee JM; Yoon JH; Han JK; Choi BI
Invest Radiol; 2013 Aug; 48(8):607-13. PubMed ID: 23538889
[TBL] [Abstract][Full Text] [Related]
14. Effect of lapatinib on hepatic parenchymal enhancement on gadoxetate disodium (EOB)-enhanced MRI scans.
Nakamura Y; Date S; Toyota N; Tani C; Honda Y; Komoto D; Tanitame K; Awai K
J Comput Assist Tomogr; 2011; 35(3):351-2. PubMed ID: 21586929
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
16. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement?
Motosugi U; Ichikawa T; Sou H; Sano K; Tominaga L; Kitamura T; Araki T
J Magn Reson Imaging; 2009 Nov; 30(5):1042-6. PubMed ID: 19856436
[TBL] [Abstract][Full Text] [Related]
17. Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.
Seo HJ; Kim MJ; Lee JD; Chung WS; Kim YE
Invest Radiol; 2011 Sep; 46(9):548-55. PubMed ID: 21577131
[TBL] [Abstract][Full Text] [Related]
18. Gadoxetate disodium in patients with primary sclerosing cholangitis: an analysis of hepatobiliary contrast excretion.
Ringe KI; Hinrichs J; Merkle EM; Weismüller TJ; Wacker F; Meyer BC
J Magn Reson Imaging; 2014 Jul; 40(1):106-12. PubMed ID: 24923477
[TBL] [Abstract][Full Text] [Related]
19. Functional MR cholangiography of the cystic duct and sphincter of Oddi using gadoxetate disodium: is a 30-minute delay long enough?
Corwin MT; Lamba R; McGahan JP
J Magn Reson Imaging; 2013 Apr; 37(4):993-8. PubMed ID: 23001618
[TBL] [Abstract][Full Text] [Related]
20. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI.
Kumada T; Toyoda H; Tada T; Sone Y; Fujimori M; Ogawa S; Ishikawa T
AJR Am J Roentgenol; 2011 Jul; 197(1):58-63. PubMed ID: 21701011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
